EE200000614A - Polyol-IFN-β Conjugate, Method for its Preparation, Pharmaceutical Composition and Use, and Methods for Attaching Polyethylene Glycol Residues to a Polypeptide and Use of a PEG Polypeptide Conjugate - Google Patents
Polyol-IFN-β Conjugate, Method for its Preparation, Pharmaceutical Composition and Use, and Methods for Attaching Polyethylene Glycol Residues to a Polypeptide and Use of a PEG Polypeptide ConjugateInfo
- Publication number
- EE200000614A EE200000614A EEP200000614A EEP200000614A EE200000614A EE 200000614 A EE200000614 A EE 200000614A EE P200000614 A EEP200000614 A EE P200000614A EE P200000614 A EEP200000614 A EE P200000614A EE 200000614 A EE200000614 A EE 200000614A
- Authority
- EE
- Estonia
- Prior art keywords
- conjugate
- polypeptide
- ifn
- polyol
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8333998P | 1998-04-28 | 1998-04-28 | |
PCT/US1999/009161 WO1999055377A2 (en) | 1998-04-28 | 1999-04-28 | Polyol-ifn-beta conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000614A true EE200000614A (en) | 2002-04-15 |
EE05214B1 EE05214B1 (en) | 2009-10-15 |
Family
ID=22177687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000614A EE05214B1 (en) | 1998-04-28 | 1999-04-28 | Polyol-IFN-β conjugate, process for its preparation and pharmaceutical composition |
Country Status (31)
Country | Link |
---|---|
US (3) | US6638500B1 (en) |
EP (2) | EP1421956B1 (en) |
JP (2) | JP4574007B2 (en) |
KR (1) | KR100622796B1 (en) |
CN (2) | CN100335503C (en) |
AR (1) | AR020070A1 (en) |
AT (2) | ATE275422T1 (en) |
AU (1) | AU762621B2 (en) |
BG (2) | BG64694B1 (en) |
BR (1) | BR9910023A (en) |
CA (2) | CA2330451A1 (en) |
CY (1) | CY1108022T1 (en) |
CZ (2) | CZ298597B6 (en) |
DE (2) | DE69920002T2 (en) |
DK (2) | DK1421956T3 (en) |
EA (2) | EA003789B1 (en) |
EE (1) | EE05214B1 (en) |
ES (2) | ES2285286T3 (en) |
HK (2) | HK1038194A1 (en) |
HU (1) | HUP0300548A3 (en) |
IL (1) | IL139286A (en) |
NO (2) | NO329749B1 (en) |
NZ (1) | NZ507456A (en) |
PL (2) | PL196533B1 (en) |
PT (2) | PT1075281E (en) |
SI (2) | SI1075281T1 (en) |
SK (2) | SK286217B6 (en) |
TR (2) | TR200003161T2 (en) |
TW (2) | TWI266800B (en) |
UA (2) | UA79430C2 (en) |
WO (1) | WO1999055377A2 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
PT1121156E (en) * | 1998-10-16 | 2006-05-31 | Biogen Idec Inc | CONJUGATES OF INTERFERRO-BETA-1A POLYMERS AND THEIR USES |
PT1121382E (en) * | 1998-10-16 | 2006-10-31 | Biogen Idec Inc | BETA INTERFERENCE FUSE PROTEINS AND THEIR RESPECTIVE USES |
CA2369595C (en) * | 1999-04-23 | 2010-10-05 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
US7303760B2 (en) * | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
TR200101086A3 (en) * | 1999-10-15 | 2001-08-21 | ||
US7691367B2 (en) | 1999-12-24 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd. | Branched polyalkylene glycols |
DE60139110D1 (en) | 2000-01-10 | 2009-08-13 | Maxygen Holdings Ltd | G-CSF CONJUGATES |
DK1257295T3 (en) | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Factor VII or VIIA-like molecules |
CA2436623C (en) | 2001-01-30 | 2011-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Branched polyalkylene glycols |
EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
DE60232434D1 (en) | 2001-02-27 | 2009-07-09 | Maxygen Aps | NEW INTERFERON-BETA-LIKE MOLECULES |
AU2002325819B2 (en) | 2001-07-11 | 2008-06-19 | Maxygen, Inc. | G-CSF Conjugates |
RS55578B1 (en) | 2002-01-18 | 2017-06-30 | Biogen Ma Inc | Polyalkylene polymer compounds and uses thereof |
TWI334785B (en) | 2002-06-03 | 2010-12-21 | Serono Lab | Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race |
WO2004020468A2 (en) * | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
NZ541124A (en) | 2002-12-26 | 2008-08-29 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
CA2511815A1 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
JP4847856B2 (en) | 2003-03-20 | 2011-12-28 | バイエル ヘルスケア エルエルシー | Variants of FVII and FVIIa |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
ES2428358T3 (en) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Combination therapy |
WO2005074524A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
AU2008201682B2 (en) * | 2004-02-02 | 2011-02-24 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
EP1586334A1 (en) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
NZ550926A (en) | 2004-05-17 | 2010-01-29 | Ares Trading Sa | Hydrogel interferon formulations |
EA012281B1 (en) | 2004-06-01 | 2009-08-28 | Арес Трейдинг С.А. | Method of stabilizing proteins |
UA92146C2 (en) | 2004-06-01 | 2010-10-11 | Эйрэс Трейдинг С.А. | Stabilized interferon liquid formulations |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
CN101111267B (en) | 2004-12-21 | 2012-12-05 | 尼克塔治疗公司 | Stabilized polymeric thiol reagents |
MX2007007587A (en) * | 2004-12-22 | 2007-12-11 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid. |
CN103290084A (en) | 2004-12-22 | 2013-09-11 | Ambrx公司 | Method for expression and purification of recombinant human growth hormone |
ES2553160T3 (en) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered Factor VII proteins comprising at least one non-native cysteine |
WO2007019331A2 (en) * | 2005-08-04 | 2007-02-15 | Nektar Therapeutics Al, Corporation | Conjugates of a g-csf moiety and a polymer |
WO2007022799A1 (en) | 2005-08-26 | 2007-03-01 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
BRPI0616118A2 (en) | 2005-09-01 | 2011-06-07 | Ares Trading Sa | treatment of optic neuritis |
US20070238656A1 (en) * | 2006-04-10 | 2007-10-11 | Eastman Kodak Company | Functionalized poly(ethylene glycol) |
CA2653748A1 (en) * | 2006-05-02 | 2007-11-15 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
CN101484576A (en) | 2006-05-24 | 2009-07-15 | 诺沃-诺迪斯克保健股份有限公司 | Factor IX analogues having prolonged in vivo half life |
EA020805B1 (en) | 2006-05-24 | 2015-01-30 | Мерк Сероно С.А. | Use of combination of cladribine and beta interferon for treating multiple sclerosis |
AU2008247815B2 (en) * | 2007-05-02 | 2012-09-06 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
WO2009080699A2 (en) * | 2007-12-20 | 2009-07-02 | Merck Serono S.A. | Peg-interferon-beta formulations |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
CN101525381B (en) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | Novel recombinant consensus interferon and construction of a high-efficiency expression vector thereof |
WO2009155102A2 (en) * | 2008-05-30 | 2009-12-23 | Barofold, Inc. | Method for derivatization of proteins using hydrostatic pressure |
US20110124614A1 (en) * | 2008-10-25 | 2011-05-26 | Halina Offner | Methods And Compositions For The Treatment of Autoimmune Disorders |
DE102009032179A1 (en) * | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Process for purifying interferon beta |
ES2365343B1 (en) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | USE OF CD98 AS AN ENDOMETRIAL RECEPTIVITY MARKER. |
US20130040888A1 (en) | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
AR080993A1 (en) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | FORMULATION OF PROLONGED BETA INTERFERTION ACTION WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED |
JP2013528374A (en) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Polypeptide inhibitors of VLA4 |
WO2012007324A2 (en) | 2010-07-15 | 2012-01-19 | Novo Nordisk A/S | Stabilized factor viii variants |
JP6042335B2 (en) | 2010-09-15 | 2016-12-14 | ノヴォ ノルディスク アー/エス | Factor VIII mutant with reduced cellular uptake |
EP3395356B1 (en) * | 2011-02-18 | 2021-05-19 | Stemdr Inc. | Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock |
AU2012280474A1 (en) | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
CN104080803B (en) * | 2011-10-01 | 2020-08-04 | 株式会社糖锁工学研究所 | Sugar chain-added polypeptide and pharmaceutical composition containing the same |
PE20142451A1 (en) | 2012-02-27 | 2015-02-04 | Amunix Operating Inc | COMPOSITIONS OF CONJUGATES OF XTEN AND METHODS TO MAKE THEM |
JP6112009B2 (en) | 2012-02-29 | 2017-04-12 | 東レ株式会社 | Body fluid retention inhibitor |
MY171183A (en) | 2013-03-29 | 2019-09-30 | Glytech Inc | Polypeptide glycosylated with sialylated sugar chain |
WO2016013697A1 (en) * | 2014-07-24 | 2016-01-28 | 에이비온 주식회사 | Polyethylene glycol complex of interferon-beta variant |
KR101671501B1 (en) * | 2014-07-24 | 2016-11-03 | 에이비온 주식회사 | PEGylated Interferon-beta Variants |
LT3183264T (en) | 2014-08-19 | 2021-01-11 | Biogen Ma Inc. | Pegylation method |
AU2016257724B2 (en) | 2015-05-01 | 2021-02-25 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
WO2016205618A1 (en) * | 2015-06-19 | 2016-12-22 | Morphotek, Inc. | Cys80 conjugated immunoglobulins |
AU2018254410A1 (en) * | 2017-04-17 | 2019-10-10 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
CN113382775A (en) | 2019-01-28 | 2021-09-10 | 东丽株式会社 | Polyethylene glycol modifier of hepatocyte growth factor or active fragment thereof |
WO2020158691A1 (en) | 2019-01-28 | 2020-08-06 | 東レ株式会社 | Polyethylene glycol modified body for hepatocyte growth factor or active fragment thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
WO1987000056A1 (en) * | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US5208344A (en) * | 1987-07-31 | 1993-05-04 | American Home Products Corporation | Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5711944A (en) | 1993-11-10 | 1998-01-27 | Enzon, Inc. | Interferon polymer conjugates |
KR100203824B1 (en) * | 1994-03-31 | 1999-06-15 | 스티븐 엠. 오드리 | Compositions and methods for stimulating megakaryocyte growth and differentiation |
ATE299892T1 (en) * | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
SE9503380D0 (en) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
KR0176625B1 (en) | 1996-11-05 | 1999-04-01 | 삼성전자주식회사 | Infrared object detector |
JP2001508783A (en) * | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | PEGylation method |
IL133974A0 (en) * | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
-
1999
- 1999-04-28 DE DE69920002T patent/DE69920002T2/en not_active Expired - Lifetime
- 1999-04-28 TR TR2000/03161T patent/TR200003161T2/en unknown
- 1999-04-28 IL IL13928699A patent/IL139286A/en not_active IP Right Cessation
- 1999-04-28 SI SI9930662T patent/SI1075281T1/en unknown
- 1999-04-28 NZ NZ507456A patent/NZ507456A/en not_active IP Right Cessation
- 1999-04-28 DK DK04003053T patent/DK1421956T3/en active
- 1999-04-28 DK DK99920094T patent/DK1075281T3/en active
- 1999-04-28 EA EA200001111A patent/EA003789B1/en not_active IP Right Cessation
- 1999-04-28 TR TR2001/01751T patent/TR200101751T2/en unknown
- 1999-04-28 ES ES04003053T patent/ES2285286T3/en not_active Expired - Lifetime
- 1999-04-28 AT AT99920094T patent/ATE275422T1/en active
- 1999-04-28 HU HU0300548A patent/HUP0300548A3/en unknown
- 1999-04-28 EP EP04003053A patent/EP1421956B1/en not_active Expired - Lifetime
- 1999-04-28 EA EA200300382A patent/EA005495B1/en not_active IP Right Cessation
- 1999-04-28 CA CA002330451A patent/CA2330451A1/en not_active Abandoned
- 1999-04-28 KR KR1020007011587A patent/KR100622796B1/en not_active IP Right Cessation
- 1999-04-28 CZ CZ20050048A patent/CZ298597B6/en not_active IP Right Cessation
- 1999-04-28 CA CA002565375A patent/CA2565375A1/en not_active Abandoned
- 1999-04-28 AU AU37674/99A patent/AU762621B2/en not_active Ceased
- 1999-04-28 SK SK1622-2000A patent/SK286217B6/en not_active IP Right Cessation
- 1999-04-28 ES ES99920094T patent/ES2224649T3/en not_active Expired - Lifetime
- 1999-04-28 AT AT04003053T patent/ATE365563T1/en active
- 1999-04-28 PL PL378728A patent/PL196533B1/en not_active IP Right Cessation
- 1999-04-28 SI SI9930974T patent/SI1421956T1/en unknown
- 1999-04-28 SK SK66-2007A patent/SK286654B6/en not_active IP Right Cessation
- 1999-04-28 WO PCT/US1999/009161 patent/WO1999055377A2/en active IP Right Grant
- 1999-04-28 CZ CZ20003995A patent/CZ298579B6/en not_active IP Right Cessation
- 1999-04-28 CN CNB2004100898478A patent/CN100335503C/en not_active Expired - Fee Related
- 1999-04-28 JP JP2000545574A patent/JP4574007B2/en not_active Expired - Lifetime
- 1999-04-28 PT PT99920094T patent/PT1075281E/en unknown
- 1999-04-28 EE EEP200000614A patent/EE05214B1/en not_active IP Right Cessation
- 1999-04-28 BR BR9910023-1A patent/BR9910023A/en active Search and Examination
- 1999-04-28 CN CNB998054968A patent/CN1187094C/en not_active Expired - Fee Related
- 1999-04-28 DE DE69936409T patent/DE69936409T2/en not_active Expired - Lifetime
- 1999-04-28 EP EP99920094A patent/EP1075281B1/en not_active Expired - Lifetime
- 1999-04-28 PL PL344490A patent/PL193352B1/en not_active IP Right Cessation
- 1999-04-28 UA UA20031212655A patent/UA79430C2/en unknown
- 1999-04-28 PT PT04003053T patent/PT1421956E/en unknown
- 1999-04-28 UA UA2000116719A patent/UA66857C2/en unknown
- 1999-04-29 AR ARP990101987A patent/AR020070A1/en active IP Right Grant
- 1999-07-26 TW TW093123043A patent/TWI266800B/en active
- 1999-07-26 TW TW088112596A patent/TWI232882B/en active
-
2000
- 2000-10-17 BG BG104871A patent/BG64694B1/en unknown
- 2000-10-17 BG BG109291A patent/BG65046B1/en unknown
- 2000-10-23 NO NO20005337A patent/NO329749B1/en not_active IP Right Cessation
- 2000-10-30 US US09/698,133 patent/US6638500B1/en not_active Expired - Lifetime
-
2001
- 2001-12-24 HK HK01109037A patent/HK1038194A1/en not_active IP Right Cessation
-
2003
- 2003-08-28 US US10/649,609 patent/US7357925B2/en not_active Expired - Fee Related
-
2005
- 2005-11-17 HK HK05110273A patent/HK1076115A1/en not_active IP Right Cessation
-
2007
- 2007-02-13 US US11/674,476 patent/US7700314B2/en not_active Expired - Fee Related
- 2007-07-19 CY CY20071100966T patent/CY1108022T1/en unknown
-
2010
- 2010-03-09 NO NO20100324A patent/NO332224B1/en not_active IP Right Cessation
- 2010-04-26 JP JP2010100840A patent/JP2010184929A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200000614A (en) | Polyol-IFN-β Conjugate, Method for its Preparation, Pharmaceutical Composition and Use, and Methods for Attaching Polyethylene Glycol Residues to a Polypeptide and Use of a PEG Polypeptide Conjugate | |
EE9800136A (en) | Pharmaceutical composition suitable for depot medicine, its preparation method and use | |
EE9800180A (en) | Gonadotropin-releasing hormone antagonist, its use, pharmaceutical composition and method of preparation | |
EE9800181A (en) | Gonadotropin-releasing hormone antagonist, its use, pharmaceutical composition and method of preparation | |
EE04042B1 (en) | Pharmaceutical composition of fenofibrates with high bioavailability and process for its preparation | |
NO20004741L (en) | Pharmaceutical compositions for extended peptide release and method of preparation | |
EE200000319A (en) | Site-Specific Method for the Preparation of hGRF-PEG Conjugates, hGRF-PEG Conjugates, Intermediates, Use, and Pharmaceutical Composition | |
EE05021B1 (en) | Enteric-coated pharmaceutical composition and method for its preparation | |
EE200000680A (en) | Enteric-coated pharmaceutical composition and method for its preparation | |
BR9709267A (en) | Preparation of monoclonal antibody for administration to a human pharmaceutical formulation use of a monoclonal antibody preparation and process for the manufacture of a monoclonal antibody preparation | |
EE04417B1 (en) | Oral pharmaceutical pulsatile dosage form, method of preparation and use | |
EE200100684A (en) | Indalyl-substituted benzenecarboxamides, process for their preparation, use and pharmaceutical compositions | |
ITMI950529A0 (en) | PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION | |
EE9500064A (en) | Substituted 1H-imidazoles, methods for their preparation, and pharmaceutical compositions | |
EE200000225A (en) | Aryloxyalkyl dialkylamines, methods for their preparation and pharmaceutical composition | |
HK1061841A1 (en) | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | |
EE9900112A (en) | 2-Cyanoiminoimidazole derivatives, process for their preparation, use and pharmaceutical compositions | |
EE04119B1 (en) | A pharmaceutical composition suitable for freeze-drying and a process for its preparation | |
EE9800200A (en) | Benzoylguanidine derivatives, process for their preparation, use and pharmaceutical composition | |
EE04681B1 (en) | 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition | |
IT1287174B1 (en) | PHARMACOLOGICALLY ACTIVE DIARYL-CYCLOMETHYLENPYRAZOLES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
EE03554B1 (en) | Microporous crystalline material, method of its preparation and use in detergent compositions | |
EE04683B1 (en) | Derivatives of group A streptogramins, process for their preparation and pharmaceutical composition | |
EE9900034A (en) | Arylcycloalkanecarboxylic esters, their use, pharmaceutical compositions and their preparation | |
EE03996B1 (en) | Pharmaceutical compositions, process for their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB1A | Change in the ownership or in the address of the owner | ||
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
HC1A | Change of owner name | ||
MM4A | Lapsed by not paying the annual fees |
Effective date: 20130428 |